OpenLB
Open Library of Bioscience

Nonalcoholic fatty liver and left ventricular remodelling: now the prospective evidence.

Abstract

No abstract text available.

References

1. Younossi Z, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease. Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 67:73–84.
2. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67:328–357.
3. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001; 21:3–16.
4. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in nonalcoholic fatty liver disease. J Hepatol 2008; 49:608–612.
5. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005; 42:987–1000.
6. Godoy-Matos AF, Silva WS Jr, Valerio CM. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr 2020; 12:60.
7. Fallo F, Dalla Pozza A, Tecchio M, Tona F, Sonino N, Ermani M, et al. Nonalcoholic fatty liver disease in primary aldosteronism: a pilot study. Am J Hypertens 2010; 23:2–5.
8. Fallo F, Dalla Pozza A, Sonino N, Federspil G, Ermani M, Baroselli S, et al. Nonalcoholic fatty liver disease, adiponectin and insulin resistance in dipper and nondipper essential hypertensive patients. J Hypertens 2008; 26:2191–2197.
9. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013; 10:330–344.
10. Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, Sperling LS. Nonalcoholic heart disease and the heart. J Am Coll Cardiol 2019; 73:948–963.
11. Ismaiel A, Dumityrascu DL. Cardiovascular risk in fatty liver disease: the liver-heart axis, literature review. Front Med 2019; 6:202.
12. Fargion S, Porzio M, Fracanzani AL. Nonalcoholic fatty liver disease and vascular disease: state-of-the-art. World J Gastroenterol 2014; 20:13306–13324.
13. Targher G, Bertolin IL, Padovani R, Rodella S, Zoppi ni G, Zenari L, et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 2006; 29:1325–1330.
14. Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A, et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver: should we care? Atherosclerosis 2013; 230:257–267.
15. Sookoian S, Pirola CJ. Nonalcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol 2008; 49:600–607.
16. Salvi P, Ruffini R, Agnoletti D, Magnani E, Pagliarani G, Comandini G, et al. Increased arterial stiffness in nonalcoholic fatty liver disease: the cardio-GOOSE study. J Hypertens 2010; 28:1699–1707.
17. Catena C, Bernardi S, Sabato N, Grillo A, Ermani M, Sechi LA, et al. Ambulatory arterial stiffness indices and nonalcoholic fatty liver disease in essential hypertension. Nutr Metab Cardiovasc Dis 2013; 23:389–393.
18. Li X, Shi H, Wang Z, Chang L, Zhang M, Dong X. Arterial stiffness is increased in nondiabetic, nonhypertensive postmenopausal women with nonalcoholic fatty liver disease. J Hypertens 2017; 35:1226–1234.
19. Hallsworth K, Hollingsworth KG, Thoma C, Jakovljevic D, MacGowan GA, Anstee QM, et al. Cardiac structure and function are altered in adults with nonalcoholic fatty liver disease. J Hepatol 2013; 58:757–762.
20. Petta S, Argano C, Colomba D, Camma C, Di Marco V, Cabibi D, et al. Epicardial fat, cardiac geometry and cardiac function in patients with nonalcoholic fatty liver disease: association with the severity of liver disease. J Hepatol 2015; 62:928–933.
21. Trovato FM, Martines GF, Catalano D, Musumeci G, Pirri C, Trovato GM. Echocardiography and NAFLD. Int J Cardiol 2016; 221:275–279.
22. Lee YH, Kim KJ, Yoo ME, Kim G, Yoon HJ, Jo K, et al. Association of nonalcoholic steatohepatitis with subclinical myocardial dysfunction in noncirrhotic patients. J Hepatol 2018; 68:764–772.
23. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322:1561–1566.
24. VanWagner LB, Wilcox JE, Colangelo LA, Lloyd-Jones DM, Carr JJ, Lima JA, et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study. Hepatology 2015; 62:773–783.
25. Borges-Canha M, Neves JS, Libanio D, Von-Hafe M, Vale C, Araujo-Martins M, et al. Association between nonalcoholic fatty liver disease and cardiac function and structure – a meta-analysis. Endocrine 2019; 66:467–476.
26. Wijarnpreecha K, Lou S, Panjawatanan P, Cheungpasitporn W, Pungpapong S, Lukens FJ, et al. Association between diastolic cardiac dysfunction and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Dig Liver Dis 2018; 50:1166–1175.
27. VanWagner LB, Wilcox JE, Ning H, Lewis CE, Carr JJ, Rinella ME, et al. Longitudinal association of nonalcoholic fatty liver disease with changes in myocardial structure and function: the CARDIA study. J Am Heart Assoc 2020; 9:e014279.
28. Li X, Heiskanen JS, Ma H, Heianza Y, Guo Y, Kelly TN, et al. Fatty liver index and left ventricular mass: prospective associations from two independent cohorts. J Hypertens 2021; 39:961–969.

MeSH Term